Seven AEs were rated as severe (SD dose-escalation phase, n = 2; MD dose-escalation phase, n = 5); all were considered unlikely to be related to treatment by the investigator except 1 non–life-threatening AE (hyperuricemia) in a patient receiving 2.0 mg/kg anti‒IL-20 in the MD dose-escalation phase. The gene discussed is IL20; the disease is hyperuricemia.